85/100
overall score
Total issues found:
4697Updated on: March 27, 2025
Data we analyse
Phishing and malware
4586
issues
Network security
1
issue
Email security
3
issues
Website security
107
issues
Recent critical risk issues we found
97 SSL configuration issues found
731 corporate credentials stolen
1 domains vulnerable to email spoofing
2 domains potentially spoofable
What information we check
Software patching
Web application security
Email security
Dark web exposure
Cybersecurity Benchmark
A comparison of this company’s cybersecurity ranking with industry averages and peer organizations
Phishing and malware
65
vs.
44
Network security
100
vs.
95
Email security
83
vs.
54
Website security
64
vs.
69
Get Your Free Report
Need help in fixing issues? Contact us and we will help you prepare an action plan to improve your risk rating.
Company overview
Neurocrine Biosciences (neurocrine.com) is a San Diego–based, publicly traded (NASDAQ: NBIX) biopharmaceutical company focused on developing and commercializing innovative therapies for neurological, endocrine and neuropsychiatric disorders. The company combines internal R&D and strategic partnerships to advance a diversified pipeline and has brought approved treatments to market — including the VMAT2 inhibitor Ingrezza® for movement disorders — with a focus on improving patient outcomes and addressing unmet medical needs.
Details
Website:
Industries:
Healthcare
Company size:
1001-5000 employees
Founded:
1992
Headquarters:
San Diego, California, US
Outcome reliability
We analyze billions of signals from publicly available sources to deliver validated insights into how your company is perceived externally by threat actors. These insights help security teams respond more quickly to risks, manage zero-day incidents effectively, and reduce overall exposure.
